301675-24-1 Usage
Uses
Used in Pharmaceutical Industry:
N-(1H-benzo[d]iMidazol-2-yl)-3-nitrobenzaMide is used as a potential enzyme or receptor inhibitor for its capacity to modulate biological processes. Its application in this industry is driven by the need for new therapeutic agents that can effectively target specific pathways implicated in various diseases.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, N-(1H-benzo[d]iMidazol-2-yl)-3-nitrobenzaMide serves as a valuable compound for research and development. It is utilized to explore its interactions with biological targets, potentially leading to the discovery of new drugs with improved efficacy and selectivity.
Used in Drug Development:
N-(1H-benzo[d]iMidazol-2-yl)-3-nitrobenzaMide is employed in drug development as a lead compound. Its unique structure and potential inhibitory effects make it a promising candidate for further optimization and development into a therapeutic agent for treating specific medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 301675-24-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,1,6,7 and 5 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 301675-24:
(8*3)+(7*0)+(6*1)+(5*6)+(4*7)+(3*5)+(2*2)+(1*4)=111
111 % 10 = 1
So 301675-24-1 is a valid CAS Registry Number.
301675-24-1Relevant articles and documents
BENZIMIDAZOLECARBOXAMIDES AS INHIBITORS OF FAK
-
Page/Page column 18, (2010/11/17)
This invention relates to benzimadolecarboxamides of formula (I) which are inhibitors of focal adhesion kinase, and as such are useful for treating proliferative diseases
Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4
Powers, Jay P.,Li, Shyun,Jaen, Juan C.,Liu, Jinqian,Walker, Nigel P.C.,Wang, Zhulun,Wesche, Holger
, p. 2842 - 2845 (2007/10/03)
High-throughput screening of a small-molecule compound library resulted in the identification of a novel series of N-acyl 2-aminobenzimidazoles that are potent inhibitors of interleukin-1 receptor-associated kinase-4.
Benzimidazole derivatives
-
, (2008/06/13)
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives.
